JSR Life Sciences’ Amsphere A3 Integrated into the Commercial Manufacturing of FDA-Approved Antibody Therapy
15 March 2022
Launch marks product’s first use in a commercial therapeutic
SUNNYVALE, California, March 15, 2022 – JSR Life Sciences, LLC today announced that its lead product, Amsphere™ A3 has been incorporated for the first time into the commercial manufacturing of an FDA-approved treatment.
Amsphere™ A3 is a next generation Protein-A chromatography resin that enables advanced protein separation in downstream processing of therapeutic antibodies. Since its launch in January 2016, the product has seen rapid adoption as an alternative option for downstream purification in biologics processing.
“The support provided by our global applications teams really helped make this happen,” said Hideaki Nomura, general manager of JSR Life Sciences’ Bioprocess Division. “Despite international supply chain disruptions affecting most global companies, we are in a position not only to maintain our commitments, but to expand our bioprocess purification materials to support more biologics companies in their pursuit of promising treatments for patients.”
The company is currently expanding on all fronts to facilitate increased manufacturing of biologics. Along with its first commercial launch, Amsphere™ A3 is currently being used in more than 95 clinical programs worldwide.
About JSR Life Sciences, LLC
A business unit of JSR Corporation, JSR Life Sciences, LLC is changing human health as a strategic partner and pathfinder for the life sciences industry. Rooted in a history of materials innovation, JSR Life Sciences provides specialized products, materials, and services to biopharmaceutical companies and academic researchers. Together with its world-class affiliates, JSR Life Sciences offers best-in-class integrated services that de-risk molecule selection, accelerate biologic development timelines, increase clinical success rates, and develop novel in vitro diagnostics. JSR Life Sciences’ global network of affiliates includes Crown Bioscience Inc., KBI Biopharma, Inc., Selexis SA, and MEDICAL & BIOLOGICAL LABORATORIES CO., LTD. The company operates R&D and applications labs, manufacturing facilities, and sales offices worldwide. For more information, visit JSRLifeSciences.com
Share with friends:
17 September 2024
JSR Life Sciences to Launch Amsphere™ A+, a Next-Generation Protein A Resin for Antibody Drug Purification
JSR Life Sciences, a JSR Group company, today announced the launch of its next generation protein A chromatography resin, Amsphere™ A+.
16 May 2024
JSR to make Yamanaka Hutech, a manufacturer of high-purity chemicals for semiconductors, a wholly owned subsidiary
30 November 2023
New Energy Collaborative Aims to Accelerate Creation of Low-Carbon Energy Access in Asia-Pacific for the Semiconductor Climate Consortium
2 November 2022
JSR Joins Semiconductor Climate Consortium as Founding Member
JSR Corporation today announced it has become a founding member of the new Semiconductor Climate Consortium (SCC), a group formed with other companies from across the semiconductor value chain and SEMI, the global industry association representing the electronics manufacturing and design supply chain.
13 October 2022
JSR Electronic Materials Korea to be a JSR Wholly Owned Subsidiary
SR Corporation (Representative Director, CEO: Eric Johnson, “JSR”) announced today that it has signed a Share Purchase Agreement to acquire the 60% of shares held by PERI Corporation (“PERI”) and make JSR Electronic Materials Korea Co., Ltd. ("JEMK") a wholly owned subsidiary of JSR. JEMK is a joint venture between PERI and JSR, which is the sales agent/distributor of its Electronic Materials business in Korea.
11 October 2021
